So, what does it do?

OptiBiotix Health PLC (LON:OPTI) has developed technologies that modulate the human microbiome – the collective genome of the microbes in the body. It has done so by creating microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.

With an established pipeline of microbiome modulators, the firm is working on the prevention and management of chronic lifestyle diseases such as obesity, hypercholesterolemia and lipid profiles and diabetes.

Its product roster includes weight management lines SlimBiome and SlimBiome Medical, LPLDL (cholesterol) and SweetBiotix (sweetener).

How’s it doing?

It signed 23 licensing agreements last calendar year and is expecting to maintain that sort of traction this year. In all, it has 52 of these agreements and is in 24 countries.

In 2020 the commercialisation process should be provided a boost following the launch of its SlimBiome weight management range in healthcare chain Holland and Barrett and a roll-out in Italy of a product called Ezimega 3, which contains Opibiotix’s cholesterol-lowering additive.

Headed towards profitability

In a comprehensive update on trading released on January 17, Optibiotix said total sales for the 12 months ended November 30 were £808,000. Adding in £617,000 from the disposal of a small tranche of shares it owns in sister company SkinBioTherapeutics, total income was £1.43mln, up from £541,614 a year earlier.

In terms of funding, the firm had just over £1.2mln in cash and trade debtors at the year-end, or £1.4mln once R&D tax credits are recovered. It also has a £7mln stake in SkinBioTherapeutics, which would support what it termed “capital growth”.

Corporate developments

In the Jan 17 announcement, the AIM-listed firm said it was mulling a stock market listing on NASDAQ in the US. “Given high investor and consumer interest in the microbiome in the USA and growing sales the board OptiBiotix has commissioned advisors to explore the potential of a dual NASDAQ listing,” said chief executive Stephen O’Hara.